In 2018, who released a rapid communication1 recommending the use of levofloxacin or moxifloxacin, bedaquiline, linezolid, clofazimine and cycloserine or terizidone in. Who consolidated guidelines on drugresistant tuberculosis. Based on initial isolates from persons with no prior history of tb. Bedaquiline, pretomanid and linezolid for treatment of. Division of tuberculosis elimination tb elimination multidrugresistant tuberculosis mdr tb what is tuberculosis tb. Other articles where multidrugresistant tuberculosis is discussed.
Clofazimine for the treatment of multidrugresistant tuberculosis. Aug 21, 2018 the treatment landscape for patients with multidrugresistant tuberculosis mdrtb will be dramatically transformed for the better, soumya swaminathan, md, who deputy directorgeneral for. Multidrugresistant tuberculosis treatment adherence in. The care of patients with documented multidrug resistant tuberculosis will be the focus of this report. They are also at risk for further drug resistance, which can lead to a lifethreatening diseaseextensively drugresistant tuberculosis xdrtb. Multidrugresistant tuberculosis in children is mainly the result of transmission of a mdr m.
Treatment requires a combination of multiple agents and often needs to be individualized, taking numerous considerations into account 1,2. Multidrugresistant tuberculosis mdrtb is caused by bacteria that do not respond to, at least, isoniazid and rifampicin, the two most powerful antitb medicines. Food and drug administration fda for use as part of a combination therapy in adults with pulmonary multidrugresistant tuberculosis mdr tb when an effective treatment regimen cannot otherwise be provided. National action plan for combating multidrug resistant tuberculosis. In highincome lowtbincidence countries, a disproportionate number of mdrtb cases occur in migrant foreignborn populations, with concerns about low adherence rates in these patients compared to the host nonmigrant population.
Who 2016 treatment guidelines for drugresistant tuberculosis who 2016 pdf synthesized recommendation grading system for dynamed content the dynamed team systematically monitors clinical evidence to continuously provide a synthesis of the most valid relevant evidence to support clinical decisionmaking see 7step evidencebased methodology. Treatment and outcome analysis of 205 patients with multidrugresistant tuberculosis. Improving quality of patient data for treatment of multidrug. Multidrug resistant tuberculosis mdrtb remains a serious public health problem with poor treatment outcomes. Multidrugresistant tuberculosis page 5of 42 8 primary antitb drug resistance, united states, 19932017 as of june 1, 2018 note. Who updates treatment guidelines for multidrugresistant tb. A potential threat to this is the lack of effective treatment for intolerant or nonresponsive multidrug resistant tb mdrtb, with resistance to isoniazid and rifampicin or extensively drugresistant tb xdrtb, mdrtb with additional resistance. Tb usually affects the lungs, but it can also affect other parts of the body, such as the brain, the kidneys, or the spine.
Mdrtb is a worldwide problem, being present virtually in all countries that were surveyed. Pdf pdf icon 214 kb treatment of multidrug resistant tuberculosis. Recent advances in the diagnosis and treatment of multidrug. Treatment outcomes for mdrtb patients started on treatment in. Fact sheets treatment treatment of multidrugresistant. Multidrug resistant resistant at least to rifampin and isoniazid strains of m. Multidrugresistant tuberculosis page 2 of 30 types of drug. Multidrug resistant tuberculosis course multidrug resistant tuberculosis mdrtb is difficult to treat and there exists a significant lack of information about this infectious disease.
Despite global efforts to control tuberculosis tb, multidrugresistant tb mdrtb is still a serious problem worldwide. Food and drug administration fda for use as part of a combination therapy in adults with pulmonary multidrug resistant tuberculosis mdr tb when an effective treatment regimen cannot otherwise be provided. Who treatment guidelines for drug resistant tuberculosis. Multidrugresistant tuberculosis course wma the world. The purpose of this study was to establish a baseline for measuring the impact of the programmatic management of drug resistant tb program by following up on outcomes of all patients diagnosed with multidrug resistant tuberculosis in zambia between 2012 and 2014.
Compassionate use of delamanid in combination with. Multidrug resistant tuberculosis mdrtb defined as a disease caused by mycobacterium tuberculosis resistant to at least isoniazid and rifampicin is an emergency problem in many part of world 2 3. Multidrugresistant tuberculosis mdrtb, defined by resistance to isoniazid and rifampicin, the two frontline antimicrobial drugs used to treat tb, presents substantial barriers to the eradication of global tb due to challenges around diagnosis and successful treatment 1,2,3,4. Clofazimine for the treatment of multidrugresistant. As a result, mdrtb has become a major focus for tb research in recent years 1, 2, with 480,000 new mdr. Pdf pdf icon 214 kb treatment of multidrugresistant tuberculosis. Drugresistant strains have evolved mainly due to incomplete or improper treatment.
In 2006, there were an estimated 489,000 new cases of multidrugresistant mdr tbwhich is tb that is resistant to at least isoniazid and rifampinand 116,000 estimated deaths. Treatment of drugresistant tuberculosis american journal of respiratory and critical care medicine, 2019. Suspecting the possibility of drug resistant tb, and prompt detection of all forms of drug resistant tb, not only multidrug resistant and extensively drug resistant tb, should be part of the algorithm for diagnosis and management of all patients with active tb. Thus, we read with interest the article by the collaborative group for the metaanalysis of individual patient data in mdrtb treatment2017,1 the results of which support our proposal,2 from 2015, to classify antituberculosis drugs on the basis of their. Treatment of highly drugresistant pulmonary tuberculosis. Management of multidrugresistant tuberculosis mdrtb and extensively drugresistant tuberculosis has never been easy, mirrored by the low proportion of successfully treated patients with mrdtb of just 55% globally. Multidrug resistant tuberculosis mdr tb is a significant threat to global health estimated to account for nearly half a million new cases and over 200,000 deaths in 20. A cohort study of all the mdrtb patients diagnosed at the national tb reference laboratory from across zambia. We describe demographic characteristics and identify risk factors for poor outcome among patients with mdrtb in ho chi minh city hcmc, the most populous city in vietnam. Nov 15, 2019 the document includes recommendations on the treatment of multidrug resistant tb mdrtb as well as isoniazid resistant but rifampinsusceptible tb.
The treatment landscape for patients with multidrugresistant tuberculosis mdrtb will be dramatically transformed for the better, soumya swaminathan, md. Established multidrugresistant mdrtb requires a longer duration of treatment generally 1824 months and necessitates the use of alternative chemotherapy regimens, which are more costly and. Multidrugresistant tuberculosis mdrtb, defined as disease caused by strains of mycobacterium tuberculosis resistant to at least isoniazid and rifampicin, threatens to erode progress in the global control of tb 1. Evidencebased treatment of drugsusceptible tb is the best means of preventing the development of drug resistant disease. Multidrugresistant tuberculosis management in resource. Who consolidated guidelines on drugresistant tuberculosis treatment.
Summaries of unpublished data used for the recommendations 1. Drugresistant tuberculosis curry international tuberculosis center. Outcomes of multidrugresistant tuberculosis in zambia. Clofazimine for the treatment of multidrug resistant tuberculosis. People who have multidrugresistant tb mdrtb are at high risk for treatment failure. In this study in south africa, a new agent, pretomanid, was combined with bedaquiline and linezo. The care of patients with documented multidrugresistant tuberculosis will be the focus of this report. As part of the global tb control strategy called dots directly observed treatment, shortcourse, these regimens became the standard of care even in resource. New world health organization who estimates suggest that 424,203 mdrtb cases occurred in 2004 95% confidence interval 376,019620,061, or 4. Multidrug resistant tuberculosis mdrtb is caused by bacteria that do not respond to, at least, isoniazid and rifampicin, the two most powerful antitb medicines.
Emergence and spreading of mdrtb strains is hampering efforts for the control and management of tb. The document includes recommendations on the treatment of multidrugresistant tb mdrtb as well as isoniazidresistant but rifampinsusceptible tb. Tuberculosis tb is a disease caused by bacteria that are spread from person to person through the air. Treatment and outcome analysis of 205 patients with multidrug resistant tuberculosis. Multidrugresistant tuberculosis mdrtb defined as a disease caused by mycobacterium tuberculosis resistant to at least isoniazid and rifampicin is. Who treatment guidelines for drug resistant tuberculosis, 2016 update. I shall also examine briefly the origins, biologic mechanisms, and epidemiology of drug. Multidrug resistant tuberculosis mdrtb is a growing concern in meeting global targets for tb control. Patients may have different concurrent conditions, such as hiv infection or diabetes. Tuberculosis is the common causes of infectious disease related morbidity and mortality worldwide 1.
Bedaquiline in the treatment of multidrug and extensively. Patients with multidrug resistant or rifampicin resistanttb require treatment with second line treatment regimens, which are more complex than those. Drugresistant tuberculosis tb has emerged as a significant global epidemic and poses a serious threat to hivinfected persons. Treatment of multidrug resistant tuberculosis in san francisco. Multidrugresistant tuberculosis pathology britannica. Tb 5 tuberculosis disease with drugresistant mycobacterium tuberculosis has been recognized as an important global threat,1 with a median of 9. The vision of the end tb strategy of the world health organization who is for a world free of tuberculosis tb by the year 2035.
Thus, we read with interest the article by the collaborative group for the metaanalysis of individual patient data in mdrtb treatment2017,1 the results of which support our proposal,2 from 2015, to classify antituberculosis drugs on the basis of. Treatment experience of multidrugresistant tuberculosis. Management of multidrug resistant tuberculosis mdrtb and extensively drug resistant tuberculosis has never been easy, mirrored by the low proportion of successfully treated patients with mrdtb of just 55% globally. A policy framework on decentralised and deinstitutionalised management for south africa will guide provinces in the complex process of decentralisation of drugresistant tb care and treatment. Multidrugresistant tuberculosis mdrtb, caused by mycobacterium tuberculosis that is resistant to both isoniazid and rifampicin with or without resistance to other drugs, is a phenomenon that is threatening to destabilize global tuberculosis tb control. The increasing incidence of resistance of mycobacterium tuberculosis strains to the mosteffective firstline antitb drugs is a major factor contributing to the current tb epidemic. Instead of taking daily medication on their own, patients are directly observed by a clinician or responsible family.
Multidrugresistant tuberculosis disease in northkivu. Multidrugresistant tuberculosis mdrtb oxford academic. A potential threat to this is the lack of effective treatment for intolerant or nonresponsive multidrug resistant tb mdrtb, with resistance to isoniazid and rifampicin or extensively drug resistant tb xdrtb, mdrtb with additional resistance. Treatment is difficult and best left to a specialist. The purpose of this study was to establish a baseline for measuring the impact of the programmatic management of drugresistant tb program by following up on outcomes of all patients diagnosed with multidrugresistant tuberculosis in zambia between 2012 and 2014. Multidrug resistant tuberculosis mdrtb, defined as disease caused by strains of mycobacterium tuberculosis resistant to at least isoniazid and rifampicin, threatens to erode progress in the global control of tb 1. The treatment outcomes of new, previously treated, and all mdrtb patients are shown in table 5 and figure 1. The diagnosis of mdrtb is based on mycobacterial culture followed by. National action plan for combating multidrugresistant tuberculosis. Multidrugresistant tuberculosis mdrtb, defined as tb resistant to at least isoniazid and rifampin, represents an obstacle to tb control, especially in areas where mdrtb prevalence is high. Division of tuberculosis elimination tb elimination multidrug resistant tuberculosis mdr tb what is tuberculosis tb. Some forms of tb are also resistant to secondline medications, and are called extensively drug resistant tb. A policy framework on decentralised and deinstitutionalised management for south africa will guide provinces in the complex process of decentralisation of drug resistant tb care and treatment.
Pdf diagnosis and treatment of multidrugresistant tuberculosis. Multidrug resistant tuberculosis treatment there are two types of such resistant tb infections. Tuberculosis tb is a major infectious disease killing nearly two million people, mostly in developing countries, every year. Multidrug resistant tuberculosis mdrtb is a form of tuberculosis tb infection caused by bacteria that are resistant to treatment with at least two of the most powerful firstline antitb medications drugs, isoniazid and rifampin. Patients with multidrugresistant mdr tuberculosis tb, in particular those with preextensively drugresistant prexdr and extensively drugresistant xdrtb, and those that fail standard secondline therapy, are difficult to treat and have poor longterm outcomes 1. Clinical outcome of individualised treatment of multidrugresistant tuberculosis in latvia.
A form of tuberculosis tb that is resistant to at least the two most effective tb drugs isoniazid and rifampin. Programmes and principles in treatment of multidrugresistant tuberculosis. The number of mdr tb cases in the uk has risen over the last 15 years, with ever more complex clinical cases and associated challenging public health and societal implications. Multidrugresistant tuberculosis page 5 of 30 primary mdr tb in u. The advent of multidrug resistant tuberculosis threatens this progress. Treatment requires a combination of multiple agents and often needs to be individualized, taking numerous considerations into account 1, 2. Treatment of multidrugresistant tuberculosis mdr tb charles l. The treatment of multidrugresistant tuberculosis in turkey. Risk factors for poor treatment outcomes of 2266 multidrug.
Reports of extensively drugresistant xdr tb, defined as mdr tb with. In certain high burden countries, the proportion was much higher upper graphic. Improving quality of patient data for treatment of. The resistance formed can be due to multiple of reasons such as 1 people who have already been diagnosed and are on treatment therapy leaving it halfway 2 using drugs of poor quality for treatment, taking drugs irregularly 3 and coming from areas where drug resistant tb is very common. Drug resistance may worsen further with the emergence of resistance to at least one of the. The world health organization who developed the stop tb strategy and guidelines on how to prevent, control and treat mdrtb by using available data worldwide. Treatment outcomes of multidrug resistant tuberculosis patients in estonia 46 patients, latvia 245 patients, lima 508 patients, manila 105 patients, and tomsk 143 patients. This field guide for the management of drug resistant tuberculosis is a practical tool intended to help health workers in the clinical and operational management of the disease with special focus on the introduction, implementation and management of the 9month treatment regimen for multidrug resistant tuberculosis. The ideal number of drugs needed and treatment duration are crucial issues in the management of multidrugresistant tuberculosis mdrtb. Despite global efforts to control tuberculosis tb, multidrug resistant tb mdrtb is still a serious problem worldwide. Treatment of drugresistant tb treatment options for highly drugresistant tuberculosis are limited. Multidrug resistant tuberculosis mdrtb, caused by mycobacterium tuberculosis that is resistant to both isoniazid and rifampicin with or without resistance to other drugs, is a phenomenon that is threatening to destabilize global tuberculosis tb control. Monitoring patient response to mdrtb treatment using culture.
Multidrugresistant tuberculosis and extensively drugresistant. To address this unmet medical need, there is strong interest in exploring the combined use of delamanid and bedaquiline. Predictors of poor outcomes vary in different regions. Treatment of highly drugresistant pulmonary tuberculosis nejm. Daley, md national jewish health university of colorado 2006 2008 2011 property 20 2014 2016 2019 of. Established multidrug resistant mdrtb requires a longer duration of treatment generally 1824 months and necessitates the use of alternative chemotherapy regimens, which are more costly and. Patients with multidrug resistant or rifampicin resistant tb require treatment with second line treatment regimens, which are more complex than those.
Vietnam is among the top 30 high burden of mdrtb countries. Jul 27, 2019 the ideal number of drugs needed and treatment duration are crucial issues in the management of multidrugresistant tuberculosis mdrtb. Multidrugresistant tuberculosis mdr tb is a significant threat to global health estimated to account for nearly half a million new cases and over 200,000 deaths in 20. Treatment in developed countries is expensive and involves an individualized regimen based on drug susceptibility data and use of reserve drugs. Also, in 2016 about 19% of previously treated tb cases were estimated to have either rifampicin or multi drug resistant tb. Mukherjee js, rich ml, socci ar, joseph jk, viru fa, shin ss, furin jj, becerra mc, barry dj, kim jy, et al. Multidrugresistant tuberculosis course multidrugresistant tuberculosis mdrtb is difficult to treat and there exists a significant lack of information about this infectious disease. Treatment of drug resistant tb treatment options for highly drug resistant tuberculosis are limited. Patients with multidrug resistant mdr tuberculosis tb, in particular those with preextensively drug resistant prexdr and extensively drug resistant xdrtb, and those that fail standard secondline therapy, are difficult to treat and have poor longterm outcomes 1. Clinical implications of the global multidrugresistant. The treatment of multidrug and rifampin resistant tuberculosis mdrrr tb is complex. Who treatment guidelines for drugresistant tuberculosis, 2016 update.
1069 1631 1511 629 1082 404 517 281 798 934 1254 817 518 488 570 1157 1249 1020 825 1335 1432 141 1490 1234 1342 1145 146 704 1473 828 1179 841 533 1315 1577 672 356 711 533 1291 164 539 348